JP2016520192A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520192A5 JP2016520192A5 JP2016514016A JP2016514016A JP2016520192A5 JP 2016520192 A5 JP2016520192 A5 JP 2016520192A5 JP 2016514016 A JP2016514016 A JP 2016514016A JP 2016514016 A JP2016514016 A JP 2016514016A JP 2016520192 A5 JP2016520192 A5 JP 2016520192A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- subject
- renal function
- level
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 25
- 230000003907 kidney function Effects 0.000 claims 25
- 238000000034 method Methods 0.000 claims 24
- 230000035945 sensitivity Effects 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 6
- -1 Eritoroneto Chemical compound 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 claims 2
- JLQSXXWTCJPCBC-UHFFFAOYSA-N N-methyl-6-pyridone-3-carboxamide Chemical compound CN1C=C(C(N)=O)C=CC1=O JLQSXXWTCJPCBC-UHFFFAOYSA-N 0.000 claims 2
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- AFPVVTILDKMYJF-SOVPELCUSA-N (2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-[hydroxy(sulfonyl)methyl]oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](C(O)=S(=O)=O)[C@@H](O)[C@H]1O AFPVVTILDKMYJF-SOVPELCUSA-N 0.000 claims 1
- CPXSBHKDEPPWIX-MKWJWUHGSA-N (2S)-2-amino-3-[2-[(3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-1H-indol-3-yl]propanoic acid Chemical compound C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)C1=C(C[C@H](N)C(=O)O)C2=CC=CC=C2N1 CPXSBHKDEPPWIX-MKWJWUHGSA-N 0.000 claims 1
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 claims 1
- IHCPDBBYTYJYIL-QVDQXJPCSA-N (R)-2-methylbutyrylcarnitine Chemical compound CCC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHCPDBBYTYJYIL-QVDQXJPCSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 claims 1
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 claims 1
- QFDRTQONISXGJA-UHFFFAOYSA-N 1-methyluric acid Chemical compound O=C1N(C)C(=O)NC2=C1NC(=O)N2 QFDRTQONISXGJA-UHFFFAOYSA-N 0.000 claims 1
- JTEYKUFKXGDTEU-UHFFFAOYSA-N 2,3-dihydroxy-3-methylbutanoic acid Chemical compound CC(C)(O)C(O)C(O)=O JTEYKUFKXGDTEU-UHFFFAOYSA-N 0.000 claims 1
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- QXKAIJAYHKCRRA-FLRLBIABSA-N D-xylonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-FLRLBIABSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 claims 1
- NIDVTARKFBZMOT-PEBGCTIMSA-N N(4)-acetylcytidine Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIDVTARKFBZMOT-PEBGCTIMSA-N 0.000 claims 1
- BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 claims 1
- FKTXRTPBUWLETL-QMMMGPOBSA-N N-acetyl-3-methyl-L-histidine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CN=CN1C FKTXRTPBUWLETL-QMMMGPOBSA-N 0.000 claims 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 1
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims 1
- PEDXUVCGOLSNLQ-WUJLRWPWSA-N N-acetyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(C)=O PEDXUVCGOLSNLQ-WUJLRWPWSA-N 0.000 claims 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 claims 1
- 108700016464 N-acetylcarnosine Proteins 0.000 claims 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- HFCPFJNSBPQJDP-UHFFFAOYSA-N O-3-methylglutarylcarnitine Chemical compound [O-]C(=O)CC(C)CC(=O)OC(CC(O)=O)C[N+](C)(C)C HFCPFJNSBPQJDP-UHFFFAOYSA-N 0.000 claims 1
- NXJAXUYOQLTISD-SECBINFHSA-N O-glutaroyl-L-carnitine Chemical compound C[N+](C)(C)C[C@@H](CC([O-])=O)OC(=O)CCCC(O)=O NXJAXUYOQLTISD-SECBINFHSA-N 0.000 claims 1
- LRCNOZRCYBNMEP-SECBINFHSA-N O-isobutyryl-L-carnitine Chemical compound CC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C LRCNOZRCYBNMEP-SECBINFHSA-N 0.000 claims 1
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 claims 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 claims 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- ONJSZLXSECQROL-UHFFFAOYSA-N alpha-hydroxyhippuric acid Natural products OC(=O)CNC(=O)C1=CC=CC=C1O ONJSZLXSECQROL-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- XUYANFPPYJSBPU-QMMMGPOBSA-N bisorcic Chemical compound CC(=O)NCCC[C@@H](C(O)=O)NC(C)=O XUYANFPPYJSBPU-QMMMGPOBSA-N 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- AQTYXAPIHMXAAV-UHFFFAOYSA-M guaiacol sulfate(1-) Chemical compound COC1=CC=CC=C1OS([O-])(=O)=O AQTYXAPIHMXAAV-UHFFFAOYSA-M 0.000 claims 1
- DHRNMNHPSWBJEN-UHFFFAOYSA-N hydroxyisovaleroyl carnitine Chemical compound CC(C)CC(=O)OC(O)(CC([O-])=O)C[N+](C)(C)C DHRNMNHPSWBJEN-UHFFFAOYSA-N 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000013178 mathematical model Methods 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 claims 1
- 229940099459 n-acetylmethionine Drugs 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 claims 1
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- HAEVNYBCYZZDFL-MRVPVSSYSA-N succinyl-L-carnitine Chemical compound C[N+](C)(C)C[C@@H](CC([O-])=O)OC(=O)CCC(O)=O HAEVNYBCYZZDFL-MRVPVSSYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822965P | 2013-05-14 | 2013-05-14 | |
| US61/822,965 | 2013-05-14 | ||
| PCT/US2014/037762 WO2014186311A1 (en) | 2013-05-14 | 2014-05-13 | Biomarkers related to kidney function and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520192A JP2016520192A (ja) | 2016-07-11 |
| JP2016520192A5 true JP2016520192A5 (enExample) | 2017-06-22 |
| JP6595984B2 JP6595984B2 (ja) | 2019-10-23 |
Family
ID=51898805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514016A Active JP6595984B2 (ja) | 2013-05-14 | 2014-05-13 | 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10539575B2 (enExample) |
| EP (3) | EP2997366B1 (enExample) |
| JP (1) | JP6595984B2 (enExample) |
| CN (2) | CN105209909B (enExample) |
| AU (1) | AU2014265669B2 (enExample) |
| BR (1) | BR112015028253A2 (enExample) |
| CA (2) | CA3184836A1 (enExample) |
| ES (2) | ES2702123T3 (enExample) |
| MX (2) | MX391220B (enExample) |
| WO (1) | WO2014186311A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3184836A1 (en) * | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| CN111239415B (zh) | 2013-10-17 | 2024-03-26 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| US10254272B2 (en) * | 2015-01-09 | 2019-04-09 | Global Genomics Group, LLC | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease |
| WO2016115496A1 (en) * | 2015-01-15 | 2016-07-21 | Joslin Diabetes Center | Metabolite biomarkers predictive of renal disease in diabetic patients |
| EP3355914B1 (en) | 2015-09-29 | 2024-03-06 | The General Hospital Corporation | A composition comprising bcg for reducing cholesterol. |
| US20170234874A1 (en) * | 2015-10-07 | 2017-08-17 | Clearbridge Biophotonics Pte Ltd. | Integrated visual morphology and cell protein expression using resonance-light scattering |
| US12057228B1 (en) | 2015-12-30 | 2024-08-06 | Cerner Innovation, Inc. | Predicting newly incident chronic kidney disease |
| AU2017301949B2 (en) * | 2016-07-28 | 2021-09-23 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
| EP3552022B1 (en) * | 2016-11-25 | 2021-06-09 | Implexion AB | Metabolic disorders |
| WO2018118630A1 (en) | 2016-12-19 | 2018-06-28 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
| CN108956790A (zh) * | 2017-05-18 | 2018-12-07 | 中国人民解放军第二军医大学第二附属医院 | 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用 |
| CN107132266A (zh) * | 2017-06-21 | 2017-09-05 | 佛山科学技术学院 | 一种基于随机森林的水质分类方法及系统 |
| EP3665705B1 (en) | 2017-08-08 | 2024-12-18 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| CN107326093B (zh) * | 2017-09-04 | 2020-01-21 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| CA3077029A1 (en) * | 2017-09-28 | 2019-04-04 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
| CA3089817A1 (en) * | 2018-01-19 | 2019-07-25 | Mars, Incorporated | Biomarkers and classification algorithms for chronic kidney disease in cats |
| US20210327589A1 (en) * | 2018-07-14 | 2021-10-21 | Mars, Incorporated | Biomarkers and test models for chronic kidney disease |
| WO2020171158A1 (ja) * | 2019-02-20 | 2020-08-27 | 株式会社パートナーファーム | 固相反応チップ及びこれを用いた測定方法 |
| WO2021018774A1 (en) * | 2019-07-26 | 2021-02-04 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Ergothioneine, s-methyl-ergothioneine, and uses thereof |
| CN112305089B (zh) * | 2019-07-26 | 2022-04-29 | 长沙都正生物科技股份有限公司 | 一种慢性肾病诊断生物标记物及其应用 |
| CN111487338B (zh) * | 2020-04-16 | 2022-06-10 | 中南大学湘雅二医院 | 一种与肾功能相关的无创生物标记物及其应用 |
| WO2021232211A1 (zh) * | 2020-05-19 | 2021-11-25 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| KR102697110B1 (ko) | 2020-12-07 | 2024-08-22 | 킴벌리-클라크 월드와이드, 인크. | 대사산물을 검출하기 위한 방법 및 소비자 제품 |
| CN114910587B (zh) * | 2022-05-12 | 2024-03-19 | 军科正源(上海)生物医药科技有限公司 | 一种尿液检测用高效液相-串联质谱分析方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196787A (ja) | 1989-01-25 | 1990-08-03 | Otsuka Pharmaceut Co Ltd | シュードウリジン誘導体 |
| JPH0661278B2 (ja) | 1990-09-18 | 1994-08-17 | 旭化成工業株式会社 | ミオイノシトールの高感度定量法および定量用組成物 |
| US5712084A (en) * | 1995-09-08 | 1998-01-27 | Research Corporation Technologies, Inc. | Donor kidney viability test for improved preservation |
| CN101377492B (zh) | 2007-08-29 | 2014-04-23 | 北京九强生物技术股份有限公司 | 胱抑素c测定试剂盒 |
| EP2324354B1 (en) * | 2008-08-29 | 2014-07-16 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| US9421330B2 (en) * | 2008-11-03 | 2016-08-23 | Bayer Healthcare Llc | Mitigation of contrast-induced nephropathy |
| CN104034901A (zh) * | 2008-11-22 | 2014-09-10 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| WO2010124269A1 (en) | 2009-04-24 | 2010-10-28 | National Center For Genome Resources | Methods for diagnosis of sepsis and risk of death |
| JP5197846B2 (ja) * | 2009-04-30 | 2013-05-15 | 紀陽 田仲 | 腎疾患重篤度を判定する方法又は装置若しくはその作動方法 |
| US8637482B2 (en) * | 2009-06-08 | 2014-01-28 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
| JP5757626B2 (ja) | 2009-09-04 | 2015-07-29 | 国立大学法人東北大学 | ヒトにおける新たな腎疾患マーカー物質 |
| KR20120123056A (ko) | 2009-12-20 | 2012-11-07 | 아스튜트 메디컬 인코포레이티드 | 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물 |
| WO2011146683A1 (en) * | 2010-05-19 | 2011-11-24 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| CA2802273A1 (en) | 2010-08-06 | 2012-02-09 | Pronota N.V. | Perlecan as a biomarker for renal dysfunction |
| JP5916058B2 (ja) | 2011-08-26 | 2016-05-11 | 国立大学法人東北大学 | 細胞ストレス状態のバイオマーカー |
| KR20140074293A (ko) | 2011-09-14 | 2014-06-17 | 바스프 에스이 | 신장 독성을 평가하기 위한 수단 및 방법 |
| WO2013048344A1 (en) * | 2011-09-29 | 2013-04-04 | National University Of Singapore | Urinary metabolomic markers for renal insufficiency |
| CA3184836A1 (en) * | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| AU2017301949B2 (en) * | 2016-07-28 | 2021-09-23 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
-
2014
- 2014-05-13 CA CA3184836A patent/CA3184836A1/en active Pending
- 2014-05-13 JP JP2016514016A patent/JP6595984B2/ja active Active
- 2014-05-13 EP EP14797070.1A patent/EP2997366B1/en active Active
- 2014-05-13 CA CA2911204A patent/CA2911204C/en active Active
- 2014-05-13 ES ES14797070T patent/ES2702123T3/es active Active
- 2014-05-13 CN CN201480027332.7A patent/CN105209909B/zh active Active
- 2014-05-13 AU AU2014265669A patent/AU2014265669B2/en active Active
- 2014-05-13 MX MX2019005748A patent/MX391220B/es unknown
- 2014-05-13 CN CN201910484069.9A patent/CN110196335A/zh active Pending
- 2014-05-13 WO PCT/US2014/037762 patent/WO2014186311A1/en not_active Ceased
- 2014-05-13 EP EP19176215.2A patent/EP3546940B1/en active Active
- 2014-05-13 EP EP18183240.3A patent/EP3410115A1/en not_active Withdrawn
- 2014-05-13 ES ES19176215T patent/ES2871823T3/es active Active
- 2014-05-13 MX MX2015015561A patent/MX365061B/es active IP Right Grant
- 2014-05-13 BR BR112015028253A patent/BR112015028253A2/pt not_active Application Discontinuation
- 2014-05-13 US US14/889,930 patent/US10539575B2/en active Active
-
2019
- 2019-12-02 US US16/700,098 patent/US20200103417A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520192A5 (enExample) | ||
| Lin et al. | Measuring serum total and free indoxyl sulfate and p-cresyl sulfate in chronic kidney disease using UPLC-MS/MS | |
| JP6595984B2 (ja) | 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法 | |
| Lin et al. | False-positive rate of AKI using consensus creatinine–based criteria | |
| JP2018502286A5 (enExample) | ||
| Lu et al. | Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study | |
| Nolan et al. | Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort | |
| US20190156919A1 (en) | Determining relationships between risks for biological conditions and dynamic analytes | |
| Franciosi et al. | Susceptibility to COPD: differential proteomic profiling after acute smoking | |
| WO2019209874A2 (en) | Markers of immune wellness and methods of use thereof | |
| US20250087362A1 (en) | System and method of generating a model to detect, or predict the risk of, an outcome | |
| Shah et al. | Calibration-free concentration analysis of protein biomarkers in human serum using surface plasmon resonance | |
| JP6762529B2 (ja) | 腎臓病の病態バイオマーカー | |
| RU2020134037A (ru) | Способы скрининга субъекта на риск развития хронической болезни почек и компьютерно-реализуемый способ | |
| van Donge et al. | Age‐dependent changes of kidney injury biomarkers in pediatrics | |
| Basu et al. | Improving acute kidney injury diagnostics using predictive analytics | |
| Gowrishankar et al. | Value of serum cystatin C in estimating renal function in children with non‐renal solid organ transplantation | |
| Almalky et al. | Detection of early renal injury in children with solid tumors undergoing chemotherapy by urinary neutrophil gelatinase-associated lipocalin | |
| Watanabe et al. | Albumin as a Biomarker | |
| JPWO2017056498A1 (ja) | 糖尿病性腎症の判定マーカー | |
| Islam et al. | Comparative analyses of adsorbed circulating proteins in the PMMA and PES hemodiafilters in patients on predilution online hemodiafiltration | |
| Shelke et al. | Cystatin C based eGFR-for early detection of diabetic kidney disease | |
| US20250210192A1 (en) | Methods for disease detection | |
| Razek et al. | Evaluation of red cell distribution width as a septic marker in comparison with clinical scores, C-reactive protein, and procalcitonin levels | |
| Kulshrestha et al. | Neonatal screening for aminoaciduria: Can TLC be used as an affordable method in developing countries |